These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 17190842)
1. Livedoid skin reaction probably due to imatinib therapy. Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842 [TBL] [Abstract][Full Text] [Related]
2. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia. Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001 [TBL] [Abstract][Full Text] [Related]
3. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824 [TBL] [Abstract][Full Text] [Related]
4. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Severino G; Chillotti C; De Lisa R; Del Zompo M; Ardau R Ann Pharmacother; 2005 Jan; 39(1):162-4. PubMed ID: 15546944 [TBL] [Abstract][Full Text] [Related]
6. [Imatinib-induced purpuric vasculitis]. Hamm M; Touraud JP; Mannone L; Klisnick J; Ponnelle T; Lambert D Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):765-7. PubMed ID: 14576606 [TBL] [Abstract][Full Text] [Related]
7. Desensitization to imatinib in patients with leukemia. Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754 [TBL] [Abstract][Full Text] [Related]
8. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730 [TBL] [Abstract][Full Text] [Related]
9. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia. Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457 [No Abstract] [Full Text] [Related]
10. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment. Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231 [TBL] [Abstract][Full Text] [Related]
11. Hematological and molecular response evaluation of CML patients on imatinib. Gupta A; Prasad K J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739 [TBL] [Abstract][Full Text] [Related]
12. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. Brazzelli V; Prestinari F; Roveda E; Barbagallo T; Bellani E; Vassallo C; Orlandi E; Passamonti F; Borroni G J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S240-3. PubMed ID: 16227099 [TBL] [Abstract][Full Text] [Related]
13. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review. Wahiduzzaman M; Pubalan M Dermatol Online J; 2008 Dec; 14(12):14. PubMed ID: 19265627 [TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756 [TBL] [Abstract][Full Text] [Related]
15. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Ali R; Ozkalemkas F; Kimya Y; Koksal N; Ozkocaman V; Gulten T; Yorulmaz H; Tunali A Arch Gynecol Obstet; 2009 Aug; 280(2):169-75. PubMed ID: 19083009 [TBL] [Abstract][Full Text] [Related]
16. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Tanvetyanon T; Nand S Ann Pharmacother; 2003 Dec; 37(12):1818-20. PubMed ID: 14632593 [TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995 [TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. Scheinfeld N J Drugs Dermatol; 2006 Mar; 5(3):228-31. PubMed ID: 16573254 [TBL] [Abstract][Full Text] [Related]
19. [Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib]. Sugito M; Tsukada J; Higashi T; Ohta T; Matsuura A; Kubota A; Mizobe T; Mouri F; Morimoto H; Tanaka Y Rinsho Ketsueki; 2005 Nov; 46(11):1226-8. PubMed ID: 16440809 [TBL] [Abstract][Full Text] [Related]
20. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D; Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]